Review

Mycobacterium tuberculosis virulence: insights and impact on vaccine development

Giovanni Delogu

Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Rome, Italy

Search for more papers by this author

Roberta Provvedi

Department of Molecular Medicine, University of Padova, Via Aristide Gabelli 63, 35121, Padova, Italy

Search for more papers by this author

Michela Sali

Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Rome, Italy

Search for more papers by this author

Riccardo Manganelli

*Author for correspondence:

E-mail Address: riccardo.manganelli@unipd.it

Department of Molecular Medicine, University of Padova, Via Aristide Gabelli 63, 35121, Padova, Italy

Search for more papers by this author

Published Online:29 Jun 2015https://doi.org/10.2217/fmb.15.26

View article

Abstract

ABSTRACT

The existing TB vaccine, the attenuated Mycobacterium bovis strain BCG, is effective in protecting infants from severe forms of the disease, while its efficacy in protecting adults from pulmonary TB is poor. In the last two decades, a renewed interest in TB resulted in the development of several candidate vaccines that are now entering clinical trials. However, most of these vaccines are based on a common rationale and aim to induce a strong T-cell response against Mycobacterium tuberculosis. Recent advancements in the understanding of M. tuberculosis virulence determinants and associated pathogenic strategies are opening a new and broader view of the complex interaction between this remarkable pathogen and the human host, providing insights at molecular level that could lead to a new rationale for the design of novel antitubercular vaccines. A vaccination strategy that simultaneously targets different steps in TB pathogenesis may result in improved protection and reduced TB transmission.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 WHO. Global tuberculosis report 2013. www.who.int/tb/publications/global_report/en/.Google Scholar
2 Muller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 29(3), 160–169 (2013).Crossref, Medline, CAS, Google Scholar
3 Andersen P, Doherty TM. The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3(8), 656–662 (2005).Crossref, Medline, CAS, Google Scholar
4 Younga D, Verreck FA. Creativity in tuberculosis research and discovery. Tuberculosis 92(Suppl. 1), S14–S16 (2012).Crossref, Medline, Google Scholar
5 Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33(4), 567–577 (2010).Crossref, Medline, CAS, Google Scholar
6 Wolf AJ, Desvignes L, Linas B et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205(1), 105–115 (2008).Crossref, Medline, CAS, Google Scholar
7 Gallegos AM, Pamer EG, Glickman MS. Delayed protection by ESAT-6-specific effector CD4⁺ T cells after airborne M. tuberculosis infection. J. Exp. Med. 205(10), 2359–2368 (2008).Crossref, Medline, CAS, Google Scholar
8 Barry CE 3rd, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7(12), 845–855 (2009).Crossref, Medline, CAS, Google Scholar
9 Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 37(2), 80–86 (2009).Crossref, Medline, Google Scholar
10 Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol. 17(5), 183–188 (2009).Crossref, Medline, CAS, Google Scholar
11 Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 36(3), 514–532 (2012).Crossref, Medline, CAS, Google Scholar
12 Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 64, 293–311 (2010).Crossref, Medline, CAS, Google Scholar
13 Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J. Rheumatol. Suppl. 91, 11–16 (2014).Crossref, Medline, Google Scholar
14 Hossain MM, Norazmi MN. Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection – the double-edged sword? Biomed. Res. Int. 2013, 179174 (2013).• Complete overview on the mechanisms of immune recognition of M. tuberculosis during phagocytosis.Crossref, Medline, Google Scholar
15 Rajaram MV, Ni B, Dodd CE, Schlesinger LS. Macrophage immunoregulatory pathways in tuberculosis. Semin. Immunol. 26(6), 471–485 (2014).Crossref, Medline, CAS, Google Scholar
16 Cywes C, Hoppe HC, Daffe M, Ehlers MR. Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Infect. Immun. 65(10), 4258–4266 (1997).Crossref, Medline, CAS, Google Scholar
17 Rohde KH, Veiga DF, Caldwell S, Balazsi G, Russell DG. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog. 8(6), e1002769 (2012).•• Description of the dynamical changes of the M. tuberculosis transcriptional profile during the different phases of macrophage infection.Crossref, Medline, CAS, Google Scholar
18 Via LE, Deretic D, Ulmer RJ, Hibler NS, Huber LA, Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J. Biol. Chem. 272(20), 13326–13331 (1997).Crossref, Medline, CAS, Google Scholar
19 Jayachandran R, Bosedasgupta S, Pieters J. Surviving the macrophage: tools and tricks employed by Mycobacterium tuberculosis. Curr. Top. Microbiol. Immunol. 374, 189–209 (2013).Medline, CAS, Google Scholar
20 Forrellad MA, Klepp LI, Gioffre A et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence 4(1), 3–66 (2013).Crossref, Medline, Google Scholar
21 Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H⁺-ATPase to inhibit phagosome acidification. Proc. Natl Acad. Sci. USA 108(48), 19371–19376 (2011).Crossref, Medline, CAS, Google Scholar
22 Deghmane AE, Soualhine H, Bach H et al. Lipoamide dehydrogenase mediates retention of coronin-1 on BCG vacuoles, leading to arrest in phagosome maturation. J. Cell. Sci. 120(Pt 16), 2796–2806 (2007).Crossref, Medline, CAS, Google Scholar
23 Sun J, Wang X, Lau A, Liao TY, Bucci C, Hmama Z. Mycobacterial nucleoside diphosphate kinase blocks phagosome maturation in murine RAW 264.7 macrophages. PLoS ONE 5(1), e8769 (2010).Crossref, Medline, Google Scholar
24 Puri RV, Reddy PV, Tyagi AK. Secreted acid phosphatase (SapM) of Mycobacterium tuberculosis is indispensable for arresting phagosomal maturation and growth of the pathogen in guinea pig tissues. PLoS ONE 8(7), e70514 (2013).Crossref, Medline, CAS, Google Scholar
25 Welin A, Winberg ME, Abdalla H et al. Incorporation of Mycobacterium tuberculosis lipoarabinomannan into macrophage membrane rafts is a prerequisite for the phagosomal maturation block. Infect. Immun. 76(7), 2882–2887 (2008).Crossref, Medline, CAS, Google Scholar
26 Rajni, Rao N, Meena LS. Biosynthesis and virulent behavior of lipids produced by Mycobacterium tuberculosis: LAM and cord factor: an overview. Biotec. Res. Int. 2011, 274693 (2011).Crossref, Medline, CAS, Google Scholar
27 Thi EP, Hong CJ, Sanghera G, Reiner NE. Identification of the Mycobacterium tuberculosis protein PE-PGRS62 as a novel effector that functions to block phagosome maturation and inhibit iNOS expression. Cell. Microbiol. 15(5), 795–808 (2013).Crossref, Medline, CAS, Google Scholar
28 Iantomasi R, Sali M, Cascioferro A et al. PE_PGRS30 is required for the full virulence of Mycobacterium tuberculosis. Cell. Microbiol. 14(3), 356–367 (2012).Crossref, Medline, CAS, Google Scholar
29 Rampini SK, Selchow P, Keller C, Ehlers S, Bottger EC, Sander P. LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology 154(Pt 10), 2991–3001 (2008).Crossref, Medline, CAS, Google Scholar
30 Sullivan JT, Young EF, Mccann JR, Braunstein M. The Mycobacterium tuberculosis SecA2 system subverts phagosome maturation to promote growth in macrophages. Infect. Immun. 80(3), 996–1006 (2012).Crossref, Medline, CAS, Google Scholar
31 Walburger A, Koul A, Ferrari G et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304(5678), 1800–1804 (2004).Crossref, Medline, CAS, Google Scholar
32 Casonato S, Provvedi R, Dainese E, Palu G, Manganelli R. Mycobacterium tuberculosis requires the ECF sigma factor SigE to arrest phagosome maturation. PLoS ONE 9(9), e108893 (2014).Crossref, Medline, Google Scholar
33 Master SS, Rampini SK, Davis AS et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 3(4), 224–232 (2008).Crossref, Medline, CAS, Google Scholar
34 Ferrer NL, Gomez AB, Neyrolles O, Gicquel B, Martin C. Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages. PLoS ONE 5(9), e12978 (2010).Crossref, Medline, Google Scholar
35 Arbues A, Aguilo JI, Gonzalo-Asensio J et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 31(42), 4867–4873 (2013).Crossref, Medline, CAS, Google Scholar
36 Hernandez Pando R, Aguilar LD, Smith I, Manganelli R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect. Immun. 78(7), 3168–3176 (2010).Crossref, Medline, Google Scholar
37 Aguilo JI, Alonso H, Uranga S et al. ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis. Cell. Microbiol. 15(12), 1994–2005 (2013).Crossref, Medline, CAS, Google Scholar
38 Houben D, Demangel C, Van Ingen J et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell. Microbiol. 14(8), 1287–1298 (2012).Crossref, Medline, CAS, Google Scholar
39 De Jonge MI, Pehau-Arnaudet G, Fretz MM et al. ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J. Bacteriol. 189(16), 6028–6034 (2007).Crossref, Medline, CAS, Google Scholar
40 Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46(3), 709–717 (2002).Crossref, Medline, CAS, Google Scholar
41 Bottai D, Majlessi L, Simeone R et al. ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis. J. Infect. Dis. 203(8), 1155–1164 (2011).Crossref, Medline, CAS, Google Scholar
42 Behar SM, Martin CJ, Booty MG et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 4(3), 279–287 (2011).Crossref, Medline, CAS, Google Scholar
43 Seimon TA, Kim MJ, Blumenthal A et al. Induction of ER stress in macrophages of tuberculosis granulomas. PLoS ONE 5(9), e12772 (2010).Crossref, Medline, Google Scholar
44 Sohn H, Kim JS, Shin SJ et al. Targeting of Mycobacterium tuberculosis heparin-binding hemagglutinin to mitochondria in macrophages. PLoS Pathog. 7(12), e1002435 (2011).Crossref, Medline, CAS, Google Scholar
45 Aguilo N, Marinova D, Martin C, Pardo J. ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question. Front. Cell. Infect. Microbiol. 3, 88 (2013).Crossref, Medline, CAS, Google Scholar
46 Miller JL, Velmurugan K, Cowan MJ, Briken V. The type I NADH dehydrogenase of Mycobacterium tuberculosis counters phagosomal NOX2 activity to inhibit TNF-alpha-mediated host cell apoptosis. PLoS Pathog. 6(4), e1000864 (2010).Crossref, Medline, Google Scholar
47 Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11(1), 81–90 (2012).Crossref, Medline, CAS, Google Scholar
48 Hinchey J, Lee S, Jeon BY et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117(8), 2279–2288 (2007).Crossref, Medline, CAS, Google Scholar
49 Hinchey J, Jeon BY, Alley H et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS ONE 6(1), e15857 (2011).Crossref, Medline, CAS, Google Scholar
50 Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis 90(6), 361–366 (2010).Crossref, Medline, CAS, Google Scholar
51 Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136(1), 37–49 (2009).Crossref, Medline, CAS, Google Scholar
52 Pethe K, Alonso S, Biet F et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412(6843), 190–194 (2001).Crossref, Medline, CAS, Google Scholar
53 Skerry C, Pokkali S, Pinn M et al. Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs. PLoS ONE 8(6), e66310 (2013).Crossref, Medline, CAS, Google Scholar
54 Jain SK, Paul-Satyaseela M, Lamichhane G, Kim KS, Bishai WR. Mycobacterium tuberculosis invasion and traversal across an in vitro human blood-brain barrier as a pathogenic mechanism for central nervous system tuberculosis. J. Infect. Dis. 193(9), 1287–1295 (2006).Crossref, Medline, CAS, Google Scholar
55 Magombedze G, Dowdy D, Mulder N. Latent tuberculosis: models, computational efforts and the pathogen's regulatory mechanisms during dormancy. Front. Bioeng. Biotechnol. 1, 4 (2013).Crossref, Medline, Google Scholar
56 Orme IM. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis 94(1), 8–14 (2014).• This very original paper presents a new interesting theory of M. tuberculosis pathogenesis that could help rethinking the way vaccines against tuberculosis are rationally designed.Crossref, Medline, CAS, Google Scholar
57 Buerger S, Spoering A, Gavrish E, Leslin C, Ling L, Epstein SS. Microbial scout hypothesis, stochastic exit from dormancy, and the nature of slow growers. Appl. Environ. Microbiol. 78(9), 3221–3228 (2012).Crossref, Medline, CAS, Google Scholar
58 Schuck SD, Mueller H, Kunitz F et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 4(5), e5590 (2009).Crossref, Medline, Google Scholar
59 Govender L, Abel B, Hughes EJ et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 29(1), 51–57 (2010).Crossref, Medline, CAS, Google Scholar
60 Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 3(1), e1502 (2008).Crossref, Medline, Google Scholar
61 Geluk A, Van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. Innovative strategies to identify M. tuberculosis antigens and epitopes using genome-wide analyses. Front. Immunol. 5, 256 (2014).Crossref, Medline, Google Scholar
62 Kaprelyants AS, Mukamolova GV, Ruggiero A et al. Resuscitation-promoting factors (Rpf): in search of inhibitors. Protein Pept. Lett. 19(10), 1026–1034 (2012).Crossref, Medline, CAS, Google Scholar
63 Betts JC, Lukey PT, Robb LC, Mcadam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43(3), 717–731 (2002).Crossref, Medline, CAS, Google Scholar
64 Commandeur S, Van Meijgaarden KE, Lin MY et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin. Vacc. Immunol. 18(4), 676–683 (2011).Crossref, Medline, CAS, Google Scholar
65 Serra-Vidal MM, Latorre I, Franken KL et al. Immunogenicity of 60 novel latency-related antigens of. Front. Microbiol. 5, 517 (2014).Google Scholar
66 Delogu G, Manganelli R, Brennan MJ. Critical research concepts in tuberculosis vaccine development. Clin. Microbiol. Infect. 20(Suppl. 5), 59–65 (2014).Crossref, Medline, Google Scholar
67 Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. Cold Spring Harb. Perspect. Med. 4(6), pii: a018523 (2014).Crossref, Medline, Google Scholar
68 Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8(5), e1002607 (2012).Crossref, Medline, CAS, Google Scholar
69 Brennan MJ, Stone MR, Evans T. A rational vaccine pipeline for tuberculosis. Int. J. Tuberc. Lung Dis. 16(12), 1566–1573 (2012).Crossref, Medline, CAS, Google Scholar
70 Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11(8), 633–640 (2011).Crossref, Medline, Google Scholar
71 Evans TG, Brennan MJ, Barker L, Thole J. Preventive vaccines for tuberculosis. Vaccine 31(Suppl. 2), B223–B226 (2013).Crossref, Medline, CAS, Google Scholar
72 Groschel MI, Prabowo SA, Cardona PJ, Stanford JL, Van Der Werf TS. Therapeutic vaccines for tuberculosis – a systematic review. Vaccine 32(26), 3162–3168 (2014).Crossref, Medline, Google Scholar
73 Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a Phase 1 open-label randomized clinical trial. Vaccine 31(9), 1340–1348 (2013).Crossref, Medline, CAS, Google Scholar
74 Sali M, Di Sante G, Cascioferro A et al. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect. Immun. 78(12), 5202–5213 (2010).Crossref, Medline, CAS, Google Scholar
75 Sweeney KA, Dao DN, Goldberg MF et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 17(10), 1261–1268 (2011).Crossref, Medline, CAS, Google Scholar
76 Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381(9871), 1021–1028 (2013).• This paper presents the results of the first Phase IIb clinical trial for the evaluation of a new vaccination strategy against TB in infants in a high-burden country.Crossref, Medline, CAS, Google Scholar
77 Dean G, Whelan A, Clifford D et al. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32(11), 1304–1310 (2014).Crossref, Medline, CAS, Google Scholar
78 Hoft DF, Blazevic A, Stanley J et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 30(12), 2098–2108 (2012).Crossref, Medline, CAS, Google Scholar
79 Van Dissel JT, Soonawala D, Joosten SA et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T-cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29(11), 2100–2109 (2011).Crossref, Medline, CAS, Google Scholar
80 Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin. Vaccine Immunol. 17(11), 1763–1771 (2010).Crossref, Medline, CAS, Google Scholar
81 Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2(53), 53ra74 (2010).Crossref, Medline, Google Scholar
82 Parra M, Pickett T, Delogu G et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect. Immun. 72(12), 6799–6805 (2004).Crossref, Medline, CAS, Google Scholar
83 Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J. Infect. Dev. Ctries 3(1), 5–15 (2009).Crossref, Medline, Google Scholar
84 Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106(33), 13980–13985 (2009).Crossref, Medline, CAS, Google Scholar
85 Vordermeier HM, Hewinson RG, Wilkinson RJ et al. Conserved immune recognition hierarchy of mycobacterial PE/PPE proteins during infection in natural hosts. PLoS ONE 7(8), e40890 (2012).Crossref, Medline, CAS, Google Scholar
86 Brosch R, Gordon SV, Garnier T et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl Acad. Sci. USA 104(13), 5596–5601 (2007).Crossref, Medline, CAS, Google Scholar
87 Kozak RA, Alexander DC, Liao R, Sherman DR, Behr MA. Region of difference 2 contributes to virulence of Mycobacterium tuberculosis. Infect. Immun. 79(1), 59–66 (2011).Crossref, Medline, CAS, Google Scholar
88 Gideon HP, Wilkinson KA, Rustad TR et al. Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines. PLoS Pathog. 6(12), e1001237 (2010).Crossref, Medline, CAS, Google Scholar
89 Kamath AT, Fruth U, Brennan MJ et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23(29), 3753–3761 (2005).Crossref, Medline, Google Scholar
90 Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7(5–6), 955–961 (2005).Crossref, Medline, CAS, Google Scholar
91 Martin C, Williams A, Hernandez-Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24(17), 3408–3419 (2006).Crossref, Medline, CAS, Google Scholar
92 Walker KB, Brennan MJ, Ho MM et al. The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine 28(11), 2259–2270 (2010).Crossref, Medline, CAS, Google Scholar
93 Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9(5), 533–539 (2003).Crossref, Medline, CAS, Google Scholar
94 Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115(9), 2472–2479 (2005).Crossref, Medline, CAS, Google Scholar
95 Grode L, Kursar M, Fensterle J, Kaufmann SH, Hess J. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J. Immunol. 168(4), 1869–1876 (2002).Crossref, Medline, CAS, Google Scholar
96 Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27(33), 4412–4423 (2009).Crossref, Medline, CAS, Google Scholar
97 Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 334(6062), 1488–1490 (2011).Crossref, Medline, Google Scholar
98 Serafini A, Boldrin F, Palu G, Manganelli R. Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc. J. Bacteriol. 191(20), 6340–6344 (2009).Crossref, Medline, CAS, Google Scholar
99 Serafini A, Pisu D, Palu G, Rodriguez GM, Manganelli R. The ESX-3 secretion system is necessary for iron and zinc homeostasis in Mycobacterium tuberculosis. PLoS ONE 8(10), e78351 (2013).Crossref, Medline, CAS, Google Scholar
100 Andersen P, Doherty TM. TB subunit vaccines–putting the pieces together. Microbes Infect. 7(5–6), 911–921 (2005).Crossref, Medline, CAS, Google Scholar
101 Morandi M, Sali M, Manganelli R, Delogu G. Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis. J. Infect. Dev. Ctries 7(3), 169–181 (2013).Crossref, Medline, CAS, Google Scholar
102 Goonetilleke NP, Mcshane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602–1609 (2003).Crossref, Medline, CAS, Google Scholar
103 Verreck FA, Vervenne RA, Kondova I et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4(4), e5264 (2009).Crossref, Medline, Google Scholar
104 Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72(11), 6622–6632 (2004).Crossref, Medline, CAS, Google Scholar
105 Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6–Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 23(6), 780–788 (2004).Crossref, Medline, CAS, Google Scholar
106 Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75(1), 408–416 (2007).Crossref, Medline, CAS, Google Scholar
107 Lin PL, Dietrich J, Tan E et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122(1), 303–314 (2012).Crossref, Medline, CAS, Google Scholar
108 Tchilian EZ, Desel C, Forbes EK et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant ΔureC hly+ Mycobacterium bovis BCG and modified vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect. Immun. 77(2), 622–631 (2009).Crossref, Medline, CAS, Google Scholar
109 Sali M, Dainese E, Morandi M et al. Homologous prime boosting based on intranasal delivery of non-pathogenic invasive Escherichia coli expressing MPT64, decreases Mycobacterium tuberculosis dissemination. Vaccine 32(32), 4051–4058 (2014).Crossref, Medline, CAS, Google Scholar
110 Scriba TJ, Tameris M, Mansoor N et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells. Eur J. Immunol. 40(1), 279–290 (2010).Crossref, Medline, CAS, Google Scholar
111 Mcshane H, Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis 94(2), 105–110 (2014).Crossref, Medline, Google Scholar
112 Dye C, Fine PE. A major event for new tuberculosis vaccines. Lancet 381(9871), 972–974 (2013).Crossref, Medline, Google Scholar
113 Kaufmann SH. Tuberculosis vaccine development at a divide. Curr. Opin. Pulm. Med. 20(3), 294–300 (2014).Crossref, Medline, CAS, Google Scholar
114 Andersen P, Woodworth JS. Tuberculosis vaccines – rethinking the current paradigm. Trends Immunol. 35(8), 387–395 (2014).Crossref, Medline, CAS, Google Scholar
115 Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8⁺ T cells and their role in immunity. Crit. Rev. Immunol. 26(4), 317–352 (2006).Crossref, Medline, CAS, Google Scholar
116 Shanley CA, Streicher EM, Warren RM, Victor TC, Orme IM. Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape. Vaccine 31(50), 5934–5939 (2013).Crossref, Medline, CAS, Google Scholar
117 Shi L, North R, Gennaro ML. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect. Immun. 72(4), 2420–2424 (2004).Crossref, Medline, CAS, Google Scholar
118 Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 174(7), 831–839 (2006).Crossref, Medline, CAS, Google Scholar
119 Pai M, Joshi R, Dogra S et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int. J. Tuberc. Lung Dis. 13(1), 84–92 (2009).Medline, CAS, Google Scholar
120 Orme IM. Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects. Tuberculosis doi:10.1016/j.tube.2014.10.008 (2014) (Epub ahead of print).Google Scholar
121 Etna MP, Giacomini E, Severa M, Coccia EM. Pro- and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin. Immunol. 26(6), 543–551 (2014).Crossref, Medline, CAS, Google Scholar
122 O'garra A, Redford PS, Mcnab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475–527 (2013).Crossref, Medline, Google Scholar
123 Dorhoi A, Kaufmann SH. Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation. Semin. Immunol. 26(6), 533–542 (2014).Crossref, Medline, CAS, Google Scholar
124 Comas I, Chakravartti J, Small PM et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 42(6), 498–503 (2010).•• This is a very important paper that demonstrates that genes and gene sequences encoding human T-cell epitopes in M. tuberculosis are under strong purifying selection, suggesting that M. tuberculosis benefits from recognition by human T cells.Crossref, Medline, CAS, Google Scholar
125 Lindestam Arlehamn CS, Gerasimova A, Mele F et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog. 9(1), e1003130 (2013).Crossref, Medline, Google Scholar
126 Copin R, Coscolla M, Seiffert SN et al. Sequence diversity in the pe_pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognition. mBio 5(1), e00960–00913 (2014).Crossref, Medline, Google Scholar
127 Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367(1590), 850–859 (2012).Crossref, Medline, CAS, Google Scholar
128 Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 92(Suppl. 1), S6–S13 (2012).Crossref, Medline, Google Scholar
129 Armstrong JA, Hart PD. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J. Exp. Med. 142(1), 1–16 (1975).Crossref, Medline, CAS, Google Scholar
130 Malik ZA, Denning GM, Kusner DJ. Inhibition of Ca(²⁺) signaling by Mycobacterium tuberculosis is associated with reduced phagosome–lysosome fusion and increased survival within human macrophages. J. Exp. Med. 191(2), 287–302 (2000).Crossref, Medline, CAS, Google Scholar
131 Beltran-Beck B, De La Fuente J, Garrido JM et al. Oral vaccination with heat inactivated Mycobacterium bovis activates the complement system to protect against tuberculosis. PLoS ONE 9(5), e98048 (2014).Crossref, Medline, Google Scholar
132 Fenton MJ, Riley LW, Schlesinger LS. Receptor-mediated recognition of Mycobacterium tuberculosis by host cells. In: Tuberculosis and the Tubercle Bacillus. Cole ST (Ed.). ASM Press, Washington, DC, USA, 405–426 (2008).Google Scholar
133 Prados-Rosales R, Baena A, Martinez LR et al. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J. Clin. Invest. 121(4), 1471–1483 (2011).Crossref, Medline, Google Scholar
134 Prados-Rosales R, Carreno LJ, Batista-Gonzalez A et al. Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis. mBio 5(5), e01921–01914 (2014).Crossref, Medline, CAS, Google Scholar
135 Kohama H, Umemura M, Okamoto Y et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 26(7), 924–932 (2008).Crossref, Medline, CAS, Google Scholar
136 Stylianou E, Diogo GR, Pepponi I et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur J. Immunol. 44(2), 440–449 (2014).Crossref, Medline, CAS, Google Scholar
137 Aagaard C, Hoang T, Dietrich J et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17(2), 189–194 (2011).Crossref, Medline, CAS, Google Scholar
138 Hoang T, Aagaard C, Dietrich J et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS ONE 8(12), e80579 (2013).Crossref, Medline, Google Scholar
139 Elkington PT. Tuberculosis: time for a new perspective? J. Infect. 66(4), 299–302 (2013).Crossref, Medline, Google Scholar
140 Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13(3), 250–262 (2013).• This is a very important paper that summarizes the experimental evidences for the potential role of antibodies in immunity against M. tuberculosis and provides a scientific framework that supports the development of vaccines capable of eliciting antibodies against TB.Crossref, Medline, CAS, Google Scholar
141 Teitelbaum R, Glatman-Freedman A, Chen B et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl Acad. Sci. USA 95(26), 15688–15693 (1998).Crossref, Medline, CAS, Google Scholar
142 Kruh NA, Troudt J, Izzo A, Prenni J, Dobos KM. Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS ONE 5(11), e13938 (2010).Crossref, Medline, Google Scholar
143 Zumbo A, Palucci I, Cascioferro A et al. Functional dissection of protein domains involved in the immunomodulatory properties of PE_PGRS33 of Mycobacterium tuberculosis. Pathog. Dis. 69(3), 232–239 (2013).Crossref, Medline, CAS, Google Scholar

Vol. 10, No. 7

Metrics

Downloaded 552 times

History

Published online 29 June 2015

Published in print July 2015

Information

Keywords

Financial & competing interests disclosure

G Delogu and R Manganelli are supported by the Italian Ministry of Health (MIUR 2008Y8RZTF). R Manganelli is also supported by the Italian by the European Community Seventh Framework Programme (FP7/2007–2013) under grant agreements 241745 and 260872. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download